Matthew Shaulis Takes Charge as Hansa Biopharma’s CCO and US President

Hansa Biopharma, a leader in enzyme technology for rare immunological conditions, is proud to welcome Matthew Shaulis as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc. On 16 March, Mr. Shaulis will join the Executive Committee and report to President and CEO Søren Tulstrup. His arrival marks an exciting development for the company and its continued drive to provide innovative solutions to rare immunological conditions.

Søren Tulstrup, President and CEO of Hansa Biopharma, announced the exciting addition of Matthew to the company’s leadership team. This move comes as Hansa is transforming into a world-class, integrated biotechnology company and emphasizes its commitment to building a high-performing commercial function and creating a U.S.-focused organization to bring imlifidase to the United States. Tulstrup also thanked and congratulated Henk Doude van Troostwijk, who is taking on a new role as Vice President, Commercial Excellence, for his invaluable contributions.

Matthew Shaulis brings over two decades of experience in the US and international pharmaceutical industry to Hansa Biopharma. Before joining Hansa, Matthew worked at Pfizer, where he held senior executive roles, ranging from President of the North America Oncology division, to President of Inflammation and Immunology for the International Developed Markets. His impressive resume also includes positions at Teva, Cephalon, Johnson & Johnson and Schering-Plough, where he led global strategic marketing and sales initiatives, as well as product and indication launches across multiple disease areas. With his extensive experience, Matthew is well-positioned to drive Hansa Biopharma’s global commercial and medical go-to-market model transformation.

I am thrilled to join Hansa Biopharma and be part of their incredible antibody-cleaving enzyme technology platform! This company is uniquely poised to make a difference in the lives of those affected by rare immunological diseases, who often have limited treatment options. I look forward to working with the team to establish and strengthen the U.S. organization and help achieve the global commercial objectives.

Leave a Comment